A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity

Clinical Cancer Research

Volumn 10, Issue 24, 2004, Pages 8332-8340

  Stearns, Vered ^a,c   Gallagher, Ann ^a   Kleer, Celina G ^b   Singh, Baljit ^a,e   Freedman, Matthew ^a   Haddad, Bassem R ^a   Isaacs, Claudine ^a   Warren, Robert ^a   Brown, Martha ^b   Cullen, Jennifer ^a   Trock, Brace ^a,c   Hayes, Daniel F ^a,d  

^a GEORGETOWN UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^e NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER MODEL; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENOMIC IN SITU HYBRIDIZATION; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RISK MANAGEMENT;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMOPREVENTION; FEASIBILITY STUDIES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MIDDLE AGED; MODELS, BIOLOGICAL; PILOT PROJECTS; PROSPECTIVE STUDIES; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 19944428885     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0297     Document Type: Article

References (31)

1. Hartman L, Schaid D, Woods J, et al. Efficacy of biolateral prophylactic mastectomy in women with a family history of breast cancer. N. Engl J Med 1999;340:77-84.
2. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:159-64.
3. Rebbeck TR, Lynch HT, Neuhausen S, et al. Prophylactic ooporectomy in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2002;346:1616-22.
4. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (Bethesda) 1998;90:1371-88.
5. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998;352:98-101.
6. Veronesi U, Maisonneuve P, Costa A, Rotmensz N, Boyle P. Drop-outs in tamoxifen prevention trials [letter]. Lancet 1999;353:244.
7. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-1): a randomised prevention trial. Lancet 2002;360:817-24.
8. Tan-Chiu E, Wang J, Costantino JP, et al. Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. J Natl Cancer Inst (Bethesda) 2003;95:302-7.
9. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. J Am Med Assoc 1999;281:2189-97.
10. Veronesi U, De Palo G, Marubini E, et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst (Bethesda) 1999;91:1847-56.
11. Fabian C, Zalles C, Kamel S, Zeiger S, Simon C, Kimler B. Breast cytology and biomarkers obtained by random fine needle aspiration: use in risk assessment and early chemoprevention trials. J Cell Biochem 1997;28/29 Suppl:101-10.
12. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst (Bethesda) 1989;81:1879-86.
13. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer (Phila.) 1994;73:643-51.
14. Huang K, Xuan J, Varga J, et al. MR image-based tissue analysis and its clinical applications. SPIE Med Imaging 2002;4684:424-32.
15. Ware J, Kosinski M, Keller SD. A 12-item short form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-33.
16. Stewart AL, Ware JE. Measuring functioning and well being: the medical outcomes study approach. Durham, NC: Duke University Press; 1992.
17. Froberg DG, Kane RL. Methodology for measuring health-state preferences - I: Measurement strategies. J Clin Epidemiol 1989;42:345-354.
18. Kind, P. The EuroQOL instrument: An index of health-related quality of life. In: Spiker B (ed.), Quality of life and pharmacoeconomics in clinical trials. Philadelphia, PA: Lippincott-Raven; 1996, pp 191-201.
19. Figueiredo BC, Stratakis CA, Sandrini R, et al. Comparative genomic hybridization analysis of adrenocortical tumors of childhood. J Clin Endocrinol Metab 1999;84:1116-21.
20. Comis RL, Miller JD, Aldige CR, Krebs L, Stoval E. Public attitudes toward participation in cancer clinical trials. J Clin Oncol 2003;21:830-5.
21. Singletary E, Lieberman R, Atkinson N, et al. Novel translational model for breast cancer chemoprevention study: accrual to a presurgical intervention with tamoxifen and N-[4-hydroxyphenyl] retinamide. Cancer Epidemiol Biomark Prev 2000;9:1087-90.
22. Stearns V, Coop A, Singh B, et al. A pilot surrogate endpoint biomarker trial of perillyl alcohol (POH) in breast neoplasia: Administration during the period between diagnostic biopsy and definitive surgery. Clin Cancer Res 2004;10:8332-40.
23. Fabian CJ, Kimler BF, Brady DA, et al. A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. Clin Cancer Res 2002;8:3105-17.
24. Elledge RM, Clark G, Moshin S, et al. A clinical trial to assess biomarker modulation by tamoxifen in normal and premalignant breast tissue. Breast Cancer Res Treat 2001;69:131a.
25. Harper-Wynne C, Ross G, Sacks N, et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomark Prev 2002;11:614-21.
26. Dooley WC, Ljung BM, Veronesi U, et al. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst (Bethesda) 2001;93:1624-32.
27. Evron E, Dooley WC, Umbricht CB, et al. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 2001;357:1335-6.
28. Bell KA, Van Deerlin PG, Feinberg RF, du Manoir S, Haddad BR. Diagnosis of aneuploidy in archival, paraffin-embedded pregnancy-loss tissues by comparative genomic hybridization. Fertil Steril 2001;75:374-9.
29. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68.
30. Berardo MD, Elledge RM, de Moor C, Clark GM, Osborne CK, Allred DC. bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer (Phila.) 1998;82:1296-302.
31. Elledge RM, Green S, Pugh R, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 2000;89:111-7.